When to give inj enoxaparin
Reading File
Finding Sources
Searching PubMed
enoxaparin indications clinical use
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here is a structured, evidence-based summary of when to give injection enoxaparin:
Injection Enoxaparin - Indications
Enoxaparin is a low-molecular-weight heparin (LMWH) that inhibits factor Xa (and weakly factor IIa/thrombin). It is given subcutaneously (SC) for most uses, and intravenously (IV) specifically in MI.
1. Treatment Indications (Therapeutic Dosing)
| Condition | Dose |
|---|---|
| Deep Vein Thrombosis (DVT) - treatment | 1 mg/kg SC every 12 hrs, or 1.5 mg/kg SC once daily |
| Pulmonary Embolism (PE) - treatment | 1 mg/kg SC every 12 hrs (with bridging to warfarin) |
| STEMI (ST-elevation MI) | 30 mg IV bolus + 1 mg/kg SC q12h (can be given IV in MI) |
| NSTEMI / Unstable Angina (ACS) | 1 mg/kg SC q12h for 2-8 days |
2. Prophylaxis Indications (Preventive Dosing)
| Setting | Dose |
|---|---|
| Post-operative VTE prophylaxis (hip/knee replacement, abdominal surgery) | 40 mg SC once daily or 30 mg SC q12h |
| Medical patients (bed-bound, hospitalized with heart failure, respiratory failure) | 40 mg SC once daily |
| Trauma patients (moderate-high VTE risk) | 30 mg SC q12h |
| Peri-operative (moderate VTE risk) | LMWH preferred over UFH per CHEST guidelines |
| Cancer surgery (extended prophylaxis) | Continue for up to 4 weeks post-operatively |
3. Special Populations
- Pregnancy: Drug of choice for anticoagulation because it does not cross the placenta (large size + negative charge). Dose-monitor using anti-Xa levels.
- Obesity: Weight-based dosing; monitor anti-Xa levels (therapeutic range: 0.6-1 IU/mL for BD, 1-2 IU/mL for OD dosing).
- Renal impairment (CrCl <30 mL/min): Dose reduce significantly or switch to UFH - renal excretion means accumulation risk.
4. Advantages Over Unfractionated Heparin (UFH)
- No continuous IV line needed (SC injection)
- More predictable pharmacokinetics - no routine PTT monitoring needed
- Lower risk of heparin-induced thrombocytopenia (HIT)
- Lower risk of osteoporosis
- Can be used in outpatient setting
5. Contraindications
- Active major bleeding or bleeding disorders
- History of HIT (cross-sensitivity with LMWH)
- Recent brain, eye, or spinal cord surgery
- Hypersensitivity to enoxaparin or pork products
- Use caution with spinal/epidural anesthesia - risk of epidural hematoma and permanent paraplegia
6. Monitoring
- Usually not required routinely
- Monitor anti-Xa levels in: obese patients, renal impairment, pregnancy
- Reversal agent: Protamine sulfate (partially reverses LMWH's anti-Xa activity)
Sources:
- Lippincott Illustrated Reviews: Pharmacology, p. 452-455
- Fuster and Hurst's The Heart, 15th Edition, p. (VTE/LMWH section)
- Sabiston Textbook of Surgery, Pharmacologic Prophylaxis section
This is a shared conversation. Sign in to Orris to start your own chat.